Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma

Part of paid clinical trials in Rockledge, Pennsylvania.

Sponsor
Fox Chase Cancer Center
Study ID
NCT01169532
Phase
PHASE1
Status
Completed

Conditions

  • Lymphoma
  • Unspecified Adult Solid Tumor, Protocol Specific

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • ridaforolimus — DRUG
    Given PO
  • vorinostat — DRUG
    Given PO
  • biopsy — PROCEDURE
    Optional correlative studies
  • pharmacological study — OTHER
    Correlative studies
  • laboratory biomarker analysis — OTHER
    Correlative studies

Study Details

This phase I trial is studying the side effects and best dose of giving ridaforolimus and vorinostat together in treating patients with advanced solid tumors or lymphoma. Giving ridaforolimus in combination with vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Key Dates

Start date
Oct 31, 2010
Status verified
Feb 2021
Primary completion
Mar 31, 2014
Completion
Mar 31, 2014

Study Design

Enrollment
16 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (ridaforolimus and vorinostat)
    Patients receive ridaforolimus PO once daily on days 1-5 and vorinostat PO twice daily on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Maximum Tolerated Dose (MTD) [ Time Frame: First 3 weeks of treatment ]

Locations (1)

FacilityCityStateZIPSite coordinators
Fox Chase Cancer CenterRockledgePennsylvania19046-

Find similar trials in Rockledge, PA

By research site
Fox Chase Cancer Center· Rockledge, PA

Related Studies